Olon Group Acquires Huvepharma Italia, Expanding its Pharmaceutical Manufacturing Footprint

Olon Group, a leading global manufacturer of active pharmaceutical ingredients (APIs), has acquired Huvepharma Italia Srl. This strategic acquisition marks a significant step forward in Olon’s ongoing expansion strategy, bolstering its position as a major player in the global pharmaceutical market.

Huvepharma Italia, with its plant in Garessio, Italy, specializes in the development, production, and marketing of active pharmaceutical ingredients. The company boasts a strong track record in the pharmaceutical chemicals market, with expertise in developing and producing APIs and a commitment to adopting cutting-edge technologies. The Garessio plant, notable for its automation and advanced technologies, has successfully developed the production of an important antimalarial product through advanced photo-oxidation technology and the manufacture of nanoparticles.

The acquisition of Huvepharma Italia further strengthens Olon’s manufacturing network, adding a ninth plant to its Italian operations and bringing its total reaction capacity to 3,250 cubic meters. This expansion enhances Olon’s presence and production potential, solidifying its position as a major industrial player in both Italy and Europe.

The acquisition plan outlines a complete operational integration of Huvepharma Italia and a revival of the production capacity of the Garessio plant. Olon plans to capitalize on this acquisition by bringing the plant to full production capacity through the development of new business opportunities.

Paolo Tubertini, CEO of Olon Group, emphasized the strategic importance of the acquisition, stating, “We recognized in Huvepharma Italia all the right characteristics.” He highlighted that the acquisition aligns with Olon’s medium to long-term strategy and will contribute to achieving their business objectives.

The integration of Huvepharma Italia with Olon’s existing network, which includes 12 sites worldwide and 7 research centers, will leverage Olon’s established customer portfolio, including major pharmaceutical companies, and its reputation as a reliable API supplier. This acquisition underlines Olon’s commitment to growth, consolidation, and expansion on a global scale, enhancing its product offering and further strengthening its presence in the API market.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top